The Cell and Gene Therapy Catapult (CGT Catapult) announced it has licensed data from its pluripotent stem cell development program ‘Cell Plasticity’ to Japanese food and amino acid company Ajinomoto. Through the use of process and analytical data from CGT Catapult’s program, Ajinomoto Co. was able to evaluate the adherent expansion of CGT’s human induced pluripotent stem cell (iPSC) line CGT-RCiB10 in different culture systems.
CGT Catapult has been working to develop scalable processing platforms of pluripotent stem cells and their derivatives, and support the translation of research into commercially viable advanced therapy medicinal products.
“We are thrilled that our research continues to be sought after by organizations across the globe,” Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult said. The licensing of this data to Ajinomoto highlights the benefit and skills we continue to bring to these organizations, and through them, how the Catapult is able to contribute to the advancement of technologies and medicines of the future.”